11th European Aids Conference, Madrid, Spain, 24-27 October 2007 (CONFERENCE REPORT) 11th European Aids Conference, Madrid, Spain, 24-27 October 2007 (CONFERENCE REPORT)

11th European Aids Conference, Madrid, Spain, 24-27 October 2007 (CONFERENCE REPORT‪)‬

Journal of HIV Therapy 2007, Dec, 12, 4

    • 2,99 €
    • 2,99 €

Publisher Description

New information on antiretroviral therapy demonstrates that treatment is increasingly effective and shows an improving safety profile. The increase in the number of therapeutic tools also mirrors the improvement in the ways of managing anti-HIV therapies. The sector evolves very rapidly, thus the information reported here can easily be superseded at the next meeting. Interesting data from several clinical trials on antiretroviral therapy and resistance to it were reported at this conference. With respect to antiretroviral therapy, remarkable updates on several trials were presented: the MONARK trial, the Gemini study, and the OK04 study. The MONARK trial compared ritonavir-boosted lopinavir (LPV/r) twice-daily monotherapy with LPV/r twice daily+ zidovudine/lamivudine (ZDV/3TC) in naive patients [1]. On-treatment analysis indicated that 80% of patients in the monotherapy arm met the virological response criteria (HIV-RNA 50 copies/ml at week 48 and 400 copies/ml at week 24) compared to a 98% response in the three-drug arm (P = 0.02). The factors predicting virological success in patients receiving monotherapy were analysed and it was found that the viral load decline differed between responders (-1.07 [log.sub.10]) and non-responders (+0.54 [log.sub.10]) at week 1 but not at weeks 2 and 4. In the multivariate analysis, the two factors related to the virological response were: viral load 400 copies/ml at week 4 (OR 7.59, P=0.01) and infection with B versus non-B subtype (OR 6.36, P=0.01). The virological response was reached in 87% of patients with B subtype but in only 65% of patients with non-B subtype. With regard to HIV-RNA suppression 50 copies/ml between week 20 and 48, responses were higher among patients infected with B subtypes, whereas those infected with non-B subtypes frequently reported incomplete adherence. Is this a true biological effect of non-B versus B subtype or is this effect more connected to compliance or demographic factors? Any difference in the frequency of monitoring visits has yet to be analysed.

GENRE
Health & Well-Being
RELEASED
2007
1 December
LANGUAGE
EN
English
LENGTH
11
Pages
PUBLISHER
Mediscript Ltd.
SIZE
196.9
KB

More Books by Journal of HIV Therapy

Lymphoid and Histiocytic Proliferations in Hiv-Positive Patients: Problems in Diagnosis (Editorial) (Report) Lymphoid and Histiocytic Proliferations in Hiv-Positive Patients: Problems in Diagnosis (Editorial) (Report)
2009
New Protease Inhibitors and Non-Nucleoside Reverse Transcriptase Inhibitors (Leading Article) (Drug Overview) New Protease Inhibitors and Non-Nucleoside Reverse Transcriptase Inhibitors (Leading Article) (Drug Overview)
2008
New Drugs (Leading Article) (Drug Overview) New Drugs (Leading Article) (Drug Overview)
2008
Controversies in Current Treatment Guidelines (Editorial) Controversies in Current Treatment Guidelines (Editorial)
2008
16th Conference on Retroviruses and Opportunistic Infections, Montreal, Canada, 8-11 February 2009 (Conference News) 16th Conference on Retroviruses and Opportunistic Infections, Montreal, Canada, 8-11 February 2009 (Conference News)
2009
48TH Annual ICAAC/IDSA 46th Annual Meeting, Washington DC, 25-28 October 2008 (CONFERENCE Report) (Conference News) 48TH Annual ICAAC/IDSA 46th Annual Meeting, Washington DC, 25-28 October 2008 (CONFERENCE Report) (Conference News)
2008